MindMaze Secures $125M to Accelerate Global Digital Neuro-Therapeutics Innovation

MindMaze is thrilled to announce a significant milestone in its ongoing journey to revolutionize the field of digital neuro-therapeutics, having successfully raised $125,000,000 in fresh funding. As a global leader dedicated to enhancing brain recovery, learning, and adaptation, MindMaze has consistently pushed the boundaries of neuroscience, bio-sensing, engineering, mixed reality, and artificial intelligence to create innovative digital solutions for a range of neurological conditions. With over a decade of expertise and a mission to accelerate neuro-recovery for conditions such as stroke, Alzheimer’s disease, and Parkinson’s disease, this latest funding influx positions the company to further expand its groundbreaking research initiatives and scale its unique therapeutic platforms. The investment will be pivotal in driving forward the development of its universal platform for brain health, a pioneering system that combines advanced technologies to offer FDA-cleared and CE-marked digital interventions aimed at accelerating patient recovery. Founded in 2012 by CEO Dr Tej Tadi, MindMaze has not only set industry benchmarks as the first Swiss Unicorn but has also built a global presence with strategic offices in Lausanne, Baltimore, London, Paris, and Mumbai. With the funds raised, MindMaze plans to enhance its research capabilities, broaden its clinical footprint, and explore new avenues in digital therapeutic interventions—all while maintaining its focus on patient-centric care and innovation. This funding round underscores the confidence of global investors in the company’s vision and its potential to transform neurological care, promising unprecedented advancements in the digital health landscape that will benefit millions of patients worldwide.